Preliminary pharmacokinetics and in vivo studies indicate analgesic and stress mitigation effects of a novel NMDA receptor modulator

Abstract

NMDAR channel blockers produce analgesic and antidepressant effects by preferentially inhibiting the GluN2D subtype at lower doses. Given the distinct physiological role of GluN2 subunits, we hypothesized that compounds capable of simultaneously modulating GluN2A and GluN2D subtypes in opposite directions could serve as effective analgesics with minimal cognitive adverse effects. In this translational study, we investigated the in vivo effects of CNS4, a recently discovered glutamate concentration-dependent NMDAR modulator. Pharmacokinetic data revealed that CNS4 reaches peak plasma and brain concentrations within 0.25 hours post-intraperitoneal injection, with brain concentrations reach values up to 8.4% of those in plasma (64.9 vs. 5.47 {micro}g/ml). Preliminary results showed that CNS4, a non-opioid compound, increased escape latency in mice during a hotplate assay by 1.74-fold compared to saline. In a fear conditioning (FC) experiment, CNS4 anecdotally reduced the electric shock sensation and significantly decreased stress-related defecation (fecal pellets: males, 21 vs. 1; females, 19 vs. 3). CNS4 also improved hyperarousal behavior (25 vs. 4 jumps), without affecting fear memory parameters such as freezing episodes, duration, or latency. CNS4 caused no changes in locomotion across 8 of 9 parameters studied. Remarkably, approximately 50 hours after FC training, CNS4 prevented stress-induced excessive sucrose drinking behavior by more than 2-fold both in male and female mice. These findings suggest that CNS4 penetrates brain tissue and produces pharmacological effects like those of NMDAR-targeting drugs but with a distinct mechanism, avoiding the undesirable side effects typical of traditional NMDAR blockers. Therefore, CNS4 holds potential as a novel non-opioid analgesic, warranting further investigation. SignificanceNMDA-subtype glutamate receptors are an attractive target for chronic pain and PTSD treatments as they play a critical role in forming emotional memories of stressful events. In this translational pharmacology work, we demonstrate the central analgesic and stress-mitigating characteristics of a novel glutamate concentration-biased NMDA receptor modulator, CNS4. Visual Abstract O_FIG O_LINKSMALLFIG WIDTH=194 HEIGHT=200 SRC="FIGDIR/small/600208v2_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@1447c9org.highwire.dtl.DTLVardef@174e03dorg.highwire.dtl.DTLVardef@2dd3e6org.highwire.dtl.DTLVardef@b2d46b_HPS_FORMAT_FIGEXP M_FIG C_FIG